Erratum: l -Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis 1, 2, 3, 4 (The American Journal of Clinical Nutrition (2014) 99(2) (408–422), (S0002916523049602), (10.3945/ajcn.113.062802));L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: A systematic review and meta-analysis1-4

American Journal of Clinical Nutrition

Volumn 99, Issue 2, 2014, Pages 408-422

  Chen, Yizhi ^a   Abbate, Manuela ^b   Tang, Li ^a   Cai, Guangyan ^a   Gong, Zhixiang ^c   Wei, Ribao ^a   Zhou, Jianhui ^a   Chen, Xiangmei ^a  

^a State Discipline and State Key Laboratory of Kidney Disease   (China)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Chinese PLA 532 Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CARNITINE; CHOLESTEROL; ERYTHROPOIETIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

DIET SUPPLEMENTATION; END STAGE RENAL DISEASE; HEMATOCRIT; HEMODIALYSIS; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

C-REACTIVE PROTEIN; CARNITINE; CHOLESTEROL; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 84893352410     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.114.086405     Document Type: Erratum

References (86)

1. Lynch KE, Feldman HI, Berlin JA, Flory J, Rowan CG, Brunelli SM. Effects of L-carnitine on dialysis-related hypotension and muscle cramps: A meta-analysis. Am J Kidney Dis 2008;52:962-71.
2. Reuter SE, Faull RJ, Evans AM. L-carnitine supplementation in the dialysis population: Are Australian patients missing out? Nephrology (Carlton) 2008;13:3-16.
3. Indiveri C, Iacobazzi V, Tonazzi A, Giangregorio N, Infantino V, Convertini P, Console L, Palmieri F. The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology. Mol Aspects Med 2011;32:223-33.
4. Bartel LL, Hussey JL, Shrago E. Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy. Am J Clin Nutr 1981;34:1314-20.
5. Rodriguez-Segade S, Alonso de la Pena C, Paz M, Novoa D, Romero R, Arcocha V, Del Rio R. Carnitine concentrations in dialysed and undialysed patients with chronic renal insufficiency. Ann Clin Biochem 1986;23:671-5.
6. Eknoyan G, Latos DL, Lindberg J. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 2003;41:868-76.
7. Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, Librowski T. L-carnitine-metabolic functions and meaning in humans life. Curr Drug Metab 2011;12:667-78.
8. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(5 suppl):S11-145.
9. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; end-stage renal disease quality incentive program. Final rule. Fed Regist 2011;76:627-46.
10. Agazia B, Marchini P, Liani M, Saporiti E. [Hyperlipemia in maintenance dialysis patients: New therapeutic views.] Minerva Nefrol 1980; 27:53-6 (in Italian).
11. Caruso U, Cravotto E, Tisone G. Long-term treatment with L-carnitine in uremic patients undergoing chronic hemodialysis: Effects on the lipid pattern. Curr Ther Res Clin Exp 1983;33:1098-104.
12. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yucel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant 2006;21:3211-4.
13. Emami Naini A, Moradi M, Mortazavi M, Amini Harandi A, Hadizadeh M, Shirani F, Basir Ghafoori H, Emami Naini P. Effects of oral l-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: A randomized, double-blinded, placebo-controlled trial. J Nutr Metab 2012;2012: 510483.
14. Guarnieri GF, Ranieri F, Toigo G, Vasile A, Ciman M, Rizzoli V, Moracchiello M, Campanacci L. Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr 1980;33:1489-92.
15. Khodaverdi M, Zamzami E, Mousavinasab SN, Khodaverdi S, Amirmoghadami HR, Ahmadi J. [Evaluation of the influence of intravenous carnitine on hemoglobin and hematocrit levels in end stage chronic renal failure patients under hemodialysis.] J Zanjan Univ Med Sci Health Serv 2010;18:58-66 (in Arabic).
16. Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S. Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian J Med Sci 2006;60:143-53.
17. Savica V, Santoro D, Mazzaglia G, Ciolino F, Monardo P, Calvani M, Bellinghieri G, Kopple JD. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 2005;15:225-30.
18. Steiber AL, Davis AT, Spry L, Strong J, Buss ML, Ratkiewicz MM, Weatherspoon LJ. Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients. JPEN J Parenter Enteral Nutr 2006;30:10-5.
19. Trovato GM, Ginardi V, Di Marco V, Dell Aira AE, Corsi M. Long term L-carnitine treatment of chronic anaemia of patients with end stage renal failure. Curr Ther Res 1982;31:1042-9.
20. Molyneux R, Seymour AM, Bhandari S. Value of carnitine therapy in kidney dialysis patients and effects on cardiac function from human and animal studies. Curr Drug Targets 2012;13:285-93.
21. Calo LA, Vertolli U, Davis PA, Savica V. L carnitine in hemodialysis patients. Hemodial Int 2012;16:428-34.
22. Mingorance C, Rodriguez-Rodriguez R, Justo ML, Herrera MD, de Sotomayor MA. Pharmacological effects and clinical applications of propionyl-L-carnitine. Nutr Rev 2011;69:279-90.
23. Bonomini M, Zammit V, Pusey CD, De Vecchi A, Arduini A. Pharmacological use of L-carnitine in uremic anemia: Has its full potential been exploited? Pharmacol Res 2011;63:157-64.
24. Sabri MR, Fahimi F, Hajialiasgar S, Etminan A, Nazemi S, Salehi F. Does L-carnitine improve endothelial function in hemodialysis patients? J Res Med Sci 2012;17:417-21.
25. Tabibi H, Hakeshzadeh F, Hedayati M, Malakoutian T. Effects of l-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: A randomized controlled trial. J Ren Nutr 2011;21:485-91.
26. Shakeri A, Tabibi H, Hedayati M. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int 2010;14:498-504.
27. Pacheco A, Torres R, Sanhueza ME, Elgueta L, Segovia E, Cano M. [Study of aerobic capacity in chronic hemodialized patients: Effect of L-carnitine supplementation] Med Clin (Barc) 2008;130:441-5 (in Spanish).
28. Vaux EC, Taylor DJ, Altmann P, Rajagopalan B, Graham K, Cooper R, Bonomo Y, Styles P. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and nearinfrared spectroscopy in end-stage renal disease. Nephron Clin Pract 2004;97:c41-8.
29. Chazot C, Blanc C, Hurot JM, Charra B, Jean G, Laurent G. Nutritional effects of carnitine supplementation in hemodialysis patients. Clin Nephrol 2003;59:24-30.
30. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001;37:1018-28.
31. Semeniuk J, Shalansky KF, Taylor N, Jastrzebski J, Cameron EC. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients. Clin Nephrol 2000;54:470-7.
32. Thomas S, Fischer FP, Mettang T, Pauli-Magnus C, Weber J, Kuhlmann U. Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial. Am J Kidney Dis 1999; 34:678-87.
33. Kletzmayr J, Mayer G, Legenstein E, Heinz-Peer G, Leitha T, Horl WH, Kovarik J. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int Suppl 1999;69:S93-106.
34. Caruso U, Leone L, Cravotto E, Nava D. Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: A pilot study. Dial Transplant 1998;27:498-506.
35. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, Nicora R, Ashbrook D, Kopple JD. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 1990;38:904-11.
36. Bellinghieri G, Savica V, Barbera CM, Ricciardi B, Egitto M, Torre F, Valentini G, D'Iddio S, Bagiella E, Mallamace A, et al. L-carnitine and platelet aggregation in uremic patients subjected to hemodialysis. Nephron 1990;55:28-32.
37. Yderstraede KB, Pedersen FB, Dragsholt C, Trostmann A, Laier E, Larsen HF. The effect of L-carnitine on lipid metabolism in patients on chronic haemodialysis. Nephrol Dial Transplant 1987;1:238-41.
38. Nilsson-Ehle P, Cederblad G, Fagher B, Monti M, Thysell H. Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: Lack of effect of L-carnitine supplementation. Scand J Clin Lab Invest 1985;45:179-84.
39. Fagher B, Cederblad G, Monti M, Olsson L, Rasmussen B, Thysell H. Carnitine and left ventricular function in haemodialysis patients. Scand J Clin Lab Invest 1985;45:193-8.
40. Fagher B, Cederblad G, Eriksson M, Monti M, Moritz U, Nilsson-Ehle P, Thysell H. L-carnitine and haemodialysis: Double blind study on muscle function and metabolism and peripheral nerve function. Scand J Clin Lab Invest 1985;45:169-78.
41. Weschler A, Aviram M, Levin M, Better OS, Brook JG. High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. Nephron 1984;38:120-4.
42. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: A systematic review. J Am Soc Nephrol 2002;13:708-14.
43. Suchitra MM, Ashalatha VL, Sailaja E, Rao AM, Reddy VS, Bitla AR, Sivakumar V, Rao PV. The effect of L-Carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 2011;22:1155-9.
44. Shojaei M, Djalali M, Khatami M, Siassi F, Eshraghian M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis 2011;5:114-8.
45. Hakeshzadeh F, Tabibi H, Ahmadinejad M, Malakoutian T, Hedayati M. Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. Ren Fail 2010;32:1109-14.
46. Fu RG, Wang L, Zhou JP, Ma F, Liu XD, Ge H, Zhang J. The effect of Levocarnitine on nutritional status and lipid metabolism during longterm maintenance hemodialysis. Acad J Xi'an Jiaotong Univ 2010: 203-7.
47. Fatouros IG, Douroudos I, Panagoutsos S, Pasadakis P, Nikolaidis MG, Chatzinikolaou A, Sovatzidis A, Michailidis Y, Jamurtas AZ, Mandalidis D, et al. Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc 2010;42:1809-18.
48. Biolo G, Stulle M, Bianco F, Mengozzi G, Barazzoni R, Vasile A, Panzetta G, Guarnieri G. Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 2008;23:991-7.
49. Cibulka R, Racek J, Pikner R, Rajdl D, Trefil L, Vesela E, Studenovska M, Siroka R. Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. Calcif Tissue Int 2007;81:99-106.
50. Bonomini M, Sirolli V, Dottori S, Amoroso L, Di Liberato L, Arduini A. L-carnitine inhibits a subset of platelet activation responses in chronic uraemia. Nephrol Dial Transplant 2007;22:2623-9.
51. Signorelli SS, Fatuzzo P, Rapisarda F, Neri S, Ferrante M, Oliveri Conti G, Fallico R, Di Pino L, Pennisi G, Celotta G, et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. Drugs Aging 2006;23:263-70.
52. Signorelli SS, Fatuzzo P, Rapisarda F, Neri S, Ferrante M, Oliveri Conti G, Fallico R, Di Pino L, Pennisi G, Celotta G, et al. Propionyl-L-carnitine therapy: Effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney Blood Press Res 2006;29:100-7.
53. Arduini A, Bonomini M, Clutterbuck EJ, Laffan MA, Pusey CD. Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients. Nephrol Dial Transplant 2006;21:2671-2.
54. Cibulka R, Racek J, Trefil L, Vesela E, Studenovska M, Rajdl D. [Deficit of L-carnitine in haemodialysis patients and a potential role of its suplementation]. Klin Biochem Metab 2005:29-31 (in Czech).
55. Clutterbuck EJ, Laffan M. Levocarnitine (lc) supplementation improves red blood cell survival and clinical symptoms in haemodialysis (hd) patients. J Am Soc Nephrol 2002;13:635a (abstr).
56. Sorge-Haedicke B, Goncalves-Marques M, Loew L, Samizadeh A. Routine intravenous l-carnitine-supplementation does not reduce erythorpoietin (RHEPO)-requirement in chronic hemodialysis (CHD) patients (P) with renal anemia (RA). Nephrol Dial Transplant 2001;16:A135.
57. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.
58. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C, German D. Dialysis Study I. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008;74:1461-7.
59. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German D. Dialysis Study I. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353: 238-48.
60. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-76.
61. Krane V, Wanner C. Statins, inflammation and kidney disease. Nat Rev Nephrol 2011;7:385-97.
62. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009;151:264-269, W64.
63. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. Updated March 2011. Chichester, United Kingdom: John Wiley & Sons Ltd, 2011.
64. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
65. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects metaanalyses. BMJ 2011;342:d549.
66. Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study effects in meta-analyses. Stata J 2009;9:197-210.
67. Albertazzi A, Spisni C, Del Rosso G, Gambi D, Rossini PM. [Electromyographic changes induced with oral supplements of carnitine in patients under regular periodical hemodialytic treatment.] Minerva Nefrol 1980;27:647-9 (in Italian).
68. Trivelli G, Vitali P, Girmenia S, Castelli F. Trattamento della dislipidemia dell'emodializzato con L-carnitina. [Treatment of dyslipidemia of hemodialysis with L-carnitine.] Clin Eur 1983;22:405-15 (in Italian).
69. Franco V, Linder G, Lusenti T, Bottazi L, Pecorini T, Zannoni P, Manari A, Guiducci U, Zini SM. [The usefulness of administering exogenic L-carnitine to subjects undergoing periodic hemodialysis.] Clin Eur 1985;24:278-89 (in Italian).
70. Sohn HJ, Choi GB, Yoon KI. [L-Carnitine in maintenance hemodialysis clinical, lipid and biochemical effects.] Kor J Nephrol 1992;11: 260-9 (in Korean).
71. Zilleruelo G, Kaplan T, Devitt J, Novak M. Effects of L-carnitine on the response to exercise during hemodialusis (HD). Pediatr Res 1991; 29(suppl):355a (abstr).
72. Catalano C. Short-term supplementation with l-carnitine (l-c) in chronic hemodialysis (hd) patients (pts). J Am Soc Nephrol 1999;10: 155a-6a (abstr).
73. Catalano C, Bordin V, Fabbian F, Di Landro D, Fortin B. Bg. Effects of short-term supplementation with levo-carnitine (l-c) in chronic haemodialysis (hd) patients. Nephrol Dial Transplant 1999;14:A190 (abstr).
74. Sloan RS, Kastan B, Rice SI, Sallee CW, Yuenger NJ, Smith B, Ward RA, Brier ME, Golper TA. Quality of life during and between hemodialysis treatments: Role of L-carnitine supplementation. Am J Kidney Dis 1998;32(2):265-72.
75. Mettang T, Thomas S, Kuhlmann U. L-carnitine does not alleviate uremic pruritus in hemodialysis patients. Nephron 1997;75(3):372.
76. Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995;26(5):757-64.
77. Siami G, Clinton ME, Mrak R, Griffis J, Stone W. Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 1991;57(3):306-13.
78. Ahmad S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA, Hirschberg R, Nicora R, Ashbrook DW, Kopple JD. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 1990, 38(5):912-8.
79. Bellinghieri G, Savica V, Mallamace A, Di Stefano C, Consolo F, Spagnoli LG, Villaschi S, Palmieri G, Corsi M, Maccari F. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 1983;38 (4):523-31.
80. Casciani CU, Caruso U, Cravotto E, D'Iddio S, Corsi M, Pola P, Savi L, Grilli M. L-carnitine in haemodialysed patients. Changes in lipid pattern. Arzneimittelforschung 1982;32(3):293-7.
81. Casciani CU, Caruso U, Cravotto E, Corsi M, Maccari F. Beneficial effects of L-carnitine in post-dialysis syndrome. Curr Ther Res 1982; 32(1):116-27.
82. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2012;157:263-75.
83. Deng J, Wu Q, Liao Y, Huo D, Yang Z. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: A systematic review and meta-analysis. Nephrology (Carlton) 2012;17:545-51.
84. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012;338:768-72.
85. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010;5:1010-4.
86. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009;22:70-7.